radiolabeled SSTR2 modulating peptides / Lantheus - LARVOL DELTA

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan. (PubMed, Clin Cancer Res) - "In this trial of heavily treated NETs, preliminary data are promising for the use of Lu-satoreotide tetraxetan. Additional studies are on-going to determine optimal therapeutic dose/schedule."

Journal • P1 data • Neuroendocrine Tumor • Oncology • Solid Tumor

Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer. (PubMed, Clin Cancer Res) - "A novel SST-analog, Lu-DOTA-EB-TATE, has the potential to be translated from bench to bedside for the targeted therapy of patients characterized by high uptake of SST- analogs in metastatic lesions."

Journal • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • Thyroid Gland Hurthle Cell Carcinoma

Radiolabeled Somatostatin Receptor Analog 86Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 in Thyroid Cancer Mice Models (ENDO 2019) - "...The goal of our study was to compare the diagnostic accuracy of three different radiolabeled SSTR2 analogs in DTC and MTC mouse models: JR11, an antagonist; DOTATATE, an agonist; and EB-TATE, a novel modified agonist characterized by a longer half-life in the blood... We show for the first time that a novel SSTR2 analog 86Y-EB-TATE is characterized by superior tumor uptake compared to 68Ga-DOTATATE and 68Ga-DOTA-JR11 in TC mice models. Uptake of the radiolabeled analogs not only depends on SSTR2 expression levels, but also on the tumor aggressiveness.*Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins."

Preclinical

Radiolabeled Somatostatin Receptor Analog 86Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 in Thyroid Cancer Mice Models (ENDO 2019) - "...The goal of our study was to compare the diagnostic accuracy of three different radiolabeled SSTR2 analogs in DTC and MTC mouse models: JR11, an antagonist; DOTATATE, an agonist; and EB-TATE, a novel modified agonist characterized by a longer half-life in the blood... We show for the first time that a novel SSTR2 analog 86Y-EB-TATE is characterized by superior tumor uptake compared to 68Ga-DOTATATE and 68Ga-DOTA-JR11 in TC mice models. Uptake of the radiolabeled analogs not only depends on SSTR2 expression levels, but also on the tumor aggressiveness.*Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins."

Preclinical

Radiolabeled Somatostatin Receptor Analog 86Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 in Thyroid Cancer Mice Models (ENDO 2019) - "...The goal of our study was to compare the diagnostic accuracy of three different radiolabeled SSTR2 analogs in DTC and MTC mouse models: JR11, an antagonist; DOTATATE, an agonist; and EB-TATE, a novel modified agonist characterized by a longer half-life in the blood... We show for the first time that a novel SSTR2 analog 86Y-EB-TATE is characterized by superior tumor uptake compared to 68Ga-DOTATATE and 68Ga-DOTA-JR11 in TC mice models. Uptake of the radiolabeled analogs not only depends on SSTR2 expression levels, but also on the tumor aggressiveness."

Preclinical